Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HAT1 | O14929 | 4/20 | 0.44 |
| ▸ | EP300 | Q09472 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MDH2 | P40926 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15902036 | 0.87 | KMT2A (0.57) | KMT2AMEN1HAT1EP300CYP2C9 | |
| SCHEMBL15901962 | 0.82 | CYP2C9 (0.57) | HAT1EP300CYP2C9CYP2C19MAPT | |
| SCHEMBL15902043 | 0.79 | KMT2A (0.54) | KMT2AMEN1HAT1EP300CYP2C9 | |
| SCHEMBL15902301 | 0.74 | KMT2A (0.49) | KMT2AMEN1HAT1EP300CYP2C9 | |
| SCHEMBL15902158 | 0.74 | MEN1 (0.49) | KMT2AMEN1HAT1EP300ALDH1A1 | |
| SCHEMBL15901825 | 0.73 | KMT2A (0.71) | KMT2AMEN1HAT1EP300ALDH1A1 | |
| SCHEMBL15902547 | 0.72 | KMT2A (0.72) | KMT2AMEN1HAT1EP300ALDH1A1 | |
| SCHEMBL15902147 | 0.72 | KMT2A (0.67) | KMT2AMEN1HAT1EP300ALDH1A1 | |
| SCHEMBL15902047 | 0.71 | KMT2A (0.71) | KMT2AMEN1HAT1EP300ALDH1A1 | |
| SCHEMBL14496307 | 0.70 | KMT2A (1.00) | KMT2AMEN1HAT1EP300ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-04-07 | — | — | US | disclosed |
| US-11279704-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-03-22 | — | — | US | disclosed |
| CN-108440370-B | Inhibitors of viral replication | 鲁汶天主教大学 | 2021-07-30 | — | — | CN | disclosed |
| EP-3617192-A1 | VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2020-03-04 | — | — | EP | disclosed |
| US-10550123-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2020-02-04 | — | — | US | disclosed |
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2019-11-07 | — | — | US | disclosed |
| EP-2760831-B1 | VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2019-08-07 | — | — | EP | disclosed |
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | KMT2A 2425/4885MEN1 3390/4885HAT1 3301/4885 |
| US-11279704-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | KMT2A 2425/4885MEN1 3390/4885HAT1 3301/4885 |
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | KMT2A 2425/4885MEN1 3390/4885HAT1 3301/4885 |
| US-10550123-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | KMT2A 2425/4885MEN1 3390/4885HAT1 3301/4885 |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | KMT2A 2425/4885MEN1 3390/4885HAT1 3301/4885 |
| US-12012411-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | KMT2A 2425/4885MEN1 3390/4885HAT1 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.